The global influenza diagnostics market size was valued at USD 1.74 billion in 2025 and is projected to grow from USD 1.84 billion in 2026 to USD 2.81 billion by 2034, registering a CAGR of 5.46% during the forecast period from 2026 to 2034. North America dominated the influenza diagnostics market with a market share of 39.5% in 2025.
Influenza diagnostics refers to the methods and technologies used to detect and identify influenza virus infections in patients. These diagnostic approaches include rapid antigen tests, molecular assays, polymerase chain reaction (PCR) tests, viral culture, and immunofluorescence techniques. They help healthcare professionals accurately diagnose influenza, differentiate it from other respiratory illnesses, and support timely treatment decisions. Influenza diagnostics are widely used in hospitals, clinics, laboratories, and public health settings to improve patient care, monitor outbreaks, and support disease surveillance.
Download a Free Sample To learn more about this report,
Multiplex Molecular Testing Expands Respiratory Virus Detection
Influenza diagnostics are increasingly shifting toward multiplex molecular assays that can identify influenza alongside other respiratory pathogens from a single specimen. This approach helps clinicians distinguish influenza from infections with similar symptoms and can support treatment and infection-control decisions without requiring multiple separate tests. The expansion of multi-target molecular platforms is supporting influenza diagnostics market growth across hospitals, laboratories, and other clinical settings.
For instance, in April 2025, the U.S. FDA cleared Roche Molecular Systems' cobas liat SARS-CoV-2, Influenza A/B & RSV nucleic acid test. The real-time RT-PCR assay simultaneously detects SARS-CoV-2, influenza A, influenza B, and RSV and is authorized for use with healthcare-collected respiratory specimens.
Home-Based Testing Broadens Access to Influenza Detection
Influenza diagnostics are also moving closer to consumers as regulatory clearances expand the availability of tests that can be performed outside conventional laboratories and healthcare facilities. Home-based testing can allow individuals to identify influenza infection without an initial clinic visit, potentially supporting earlier decisions about seeking medical care or managing illness. This decentralization is shaping influenza diagnostics market trends toward more accessible testing options.
For instance, in August 2025, the U.S. FDA granted 510(k) clearance to Wondfo USA's WELLlife Flu A&B Home Test. The anterior-nasal-swab test is designed for home detection of influenza A and B and received its FDA decision on August 20, 2025.
Expansion of Respiratory Testing Platforms Supports Faster Differential Diagnosis
The need to distinguish influenza from other respiratory infections is encouraging healthcare providers to adopt platforms capable of testing multiple pathogens within a single workflow. Consolidating respiratory testing can reduce the need for separate assays and provide clinicians with broader diagnostic information from one specimen. This capability is strengthening influenza diagnostics market demand, particularly where rapid differentiation between respiratory viruses can influence clinical management.
For instance, in February 2025, the FDA listed Abbott Molecular's Alinity m Resp-4-Plex among authorized respiratory molecular tests. The real-time RT-PCR platform simultaneously targets influenza A, influenza B, RSV, and SARS-CoV-2, illustrating the continued expansion of multi-analyte respiratory diagnostics.
Diagnostic Product Recalls Can Disrupt Testing Reliability
Manufacturers must maintain consistent analytical performance across reagents, instruments, sample-collection components, and production lots. Quality problems can result in invalid results or product recalls, requiring laboratories to replace affected materials and potentially interrupt established testing workflows. Such events can increase operational costs and make healthcare providers more cautious when adopting diagnostic platforms.
For instance, in April 2025, Abbott initiated a Class II recall of selected Alinity m Resp-4-Plex amplification kits. The FDA reported that the affected multiplex RT-PCR kits were subject to a recall involving testing for influenza A, influenza B, RSV, and SARS-CoV-2.
Expansion of At-Home Multiplex Respiratory Testing
The development of home tests that identify several respiratory pathogens simultaneously creates opportunities for manufacturers to move influenza diagnostics into decentralized settings. Multiplex home testing can help consumers determine whether symptoms may be associated with influenza, COVID-19, or RSV while reducing dependence on separate tests. This creates influenza diagnostics market opportunities for companies developing easy-to-use respiratory testing platforms.
For instance, in October 2025, the FDA granted 510(k) clearance to ACON Laboratories' Flowflex Plus RSV + Flu A/B + COVID Home Test. The multi-analyte antigen test is designed for home detection of RSV, influenza A/B, and SARS-CoV-2, expanding the range of respiratory pathogens that can be assessed through a single home test.
Maintaining Diagnostic Capability as Influenza Viruses Evolve
Influenza diagnostics must remain capable of detecting circulating viruses as influenza viruses undergo genetic and antigenic changes. This creates an ongoing requirement for surveillance, assay evaluation, and validation against emerging strains. Diagnostic developers must therefore balance broad detection capability with sufficient specificity to identify clinically relevant influenza variants and distinguish them from other influenza A viruses.
For instance, in March 2025, the FDA emphasized that most seasonal influenza tests may detect influenza A/H5N1 but that only tests specifically designed for subtyping can determine whether an individual has seasonal influenza A or influenza A/H5. The distinction highlights the continuing challenge of adapting diagnostic strategies for emerging influenza threats.
Molecular Diagnostic Test Segment Dominated the Influenza Diagnostics Market with 54.8% Share in 2025
The molecular diagnostic test segment dominated the global influenza diagnostics market with a 54.8% share in 2025, driven by its high sensitivity, accuracy, and ability to rapidly detect influenza viruses, even in the early stages of infection. Molecular diagnostic techniques enable healthcare professionals to distinguish between influenza strains with greater precision, supporting timely treatment decisions and effective infection control. Growing adoption of advanced laboratory technologies, increasing demand for rapid and reliable diagnosis, and continued investments in molecular testing infrastructure continue to strengthen the demand for this segment.
The traditional diagnostic test segment continues to maintain a significant presence in the influenza diagnostics market due to its affordability, ease of use, and widespread availability across hospitals, clinics, and diagnostic laboratories. Rapid Influenza Diagnostic Tests (RIDTs) remain widely used for point-of-care screening because they provide quick results. Cell culture methods continue to support virus isolation and surveillance activities, while direct fluorescent antibody (DFA) tests and serological assays remain valuable in specific clinical and research settings where confirmatory or retrospective diagnosis is required.
RT-PCR Segment Dominated the Molecular Diagnostic Test Market with 61.3% Share in 2025
Within molecular diagnostics, the RT-PCR segment dominated the market with a 61.3% share in 2025 due to its exceptional accuracy, high sensitivity, and ability to detect influenza viruses within a short timeframe. RT-PCR has become the reference standard for influenza diagnosis in many healthcare settings because it supports early detection, differentiates influenza virus subtypes, and improves clinical decision-making.
The isothermal nucleic acid amplification technology (INNAT) segment continues to witness strong growth by offering faster testing with simplified workflows and minimal laboratory infrastructure requirements. Other molecular tests also contribute to the market by providing specialized diagnostic capabilities for research laboratories and advanced clinical applications.
LAMP Segment is Emerging as the Fastest-Growing INNAT Technology
Within the INNAT segment, loop-mediated isothermal amplification (LAMP) is witnessing particularly strong adoption because it delivers rapid and highly accurate molecular testing without requiring sophisticated thermal cycling equipment. The TMA segment continues to support high-throughput molecular testing in clinical laboratories, while NASBA remains valuable for RNA amplification in infectious disease diagnostics. Other INNAT technologies continue to expand as diagnostic developers introduce innovative molecular platforms designed to improve testing speed, accessibility, and operational efficiency.
Request Customizationto receive a tailored report.
Influenza A Segment is Projected to Register the Fastest Growth in the Influenza Diagnostics Market at a CAGR of 7.3%
The influenza A segment is projected to register the fastest growth in the influenza diagnostics market at a CAGR of 7.3% during 2026–2034, driven by its widespread prevalence, higher transmission rates, and greater potential to cause seasonal epidemics and occasional pandemics. Healthcare providers continue to prioritize rapid detection of Influenza A infections to enable early antiviral treatment, improve patient outcomes, and strengthen public health surveillance. Increasing government monitoring programs and improvements in molecular diagnostic technologies continue to support the expansion of this segment.
The influenza B segment continues to account for a substantial share of the market due to its regular contribution to seasonal influenza outbreaks. Although generally less widespread than Influenza A, accurate diagnosis of Influenza B remains essential for effective patient management, surveillance programs, and vaccination strategies.
Hospital Segment Dominated the Influenza Diagnostics Market with 38.6% Share in 2025
The hospital segment dominated the global influenza diagnostics market with a 38.6% share in 2025, driven by the high volume of patients requiring laboratory-confirmed influenza diagnosis and comprehensive clinical care. Hospitals continue to invest in advanced diagnostic technologies to enable rapid detection, support timely treatment decisions, reduce hospital-acquired infections, and improve patient outcomes. The availability of sophisticated laboratory infrastructure and skilled healthcare professionals further reinforces the segment's leading position.
The point-of-care testing segment continues to witness rapid growth as healthcare providers increasingly adopt portable diagnostic solutions that deliver results within minutes, enabling faster clinical decision-making in emergency departments, outpatient clinics, and community healthcare settings. The diagnostic centers segment remains an important contributor by providing specialized influenza testing services with high diagnostic accuracy and laboratory efficiency. The other segment, including public health laboratories, academic institutions, and research organizations, continues to support influenza surveillance, epidemiological studies, and the development of next-generation diagnostic technologies.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global influenza diagnostics market, representing 39.5% of total revenue and reaching USD 0.69 billion in 2025. The region continues to lead due to its advanced healthcare infrastructure, widespread availability of rapid diagnostic technologies, and strong focus on infectious disease surveillance. Increasing seasonal influenza testing, growing awareness of early disease detection, and continuous investments in molecular diagnostic technologies continue to support market growth across the region.
The US market was valued at approximately USD 0.60 billion in 2025, making it the largest contributor in North America. High testing volumes, increasing adoption of rapid molecular diagnostic assays, expanding public health initiatives, and strong investments in clinical laboratory infrastructure continue to strengthen market growth.
Canada's market reached approximately USD 0.09 billion in 2025. Growing emphasis on disease surveillance, rising use of point-of-care diagnostic tests, and continuous improvements in healthcare infrastructure are contributing to steady market growth.
Unlock Regional Insightsto access country-level data, & regional trends.
Asia Pacific accounted for 21.8% of the global influenza diagnostics market, valued at USD 0.38 billion in 2025, and is projected to register the fastest CAGR of 8.5% during the forecast period. Rising healthcare expenditure, increasing awareness of infectious disease management, expanding diagnostic laboratory networks, and improving access to advanced testing technologies continue to drive regional market growth. Government initiatives to strengthen public health systems are further supporting market expansion.
Japan's market generated approximately USD 0.07 billion in 2025. Strong seasonal influenza surveillance programs, widespread adoption of rapid diagnostic tests, and advanced healthcare infrastructure continue to support market growth.
China accounted for the largest share of the Asia Pacific market, reaching approximately USD 0.22 billion in 2025. Expanding healthcare infrastructure, increasing investment in molecular diagnostics, growing public health awareness, and rising demand for rapid influenza testing continue to drive market expansion.
Europe represented 27.4% of the global influenza diagnostics market, reaching USD 0.48 billion in 2025, and is projected to grow at a CAGR of 6.6% during the forecast period. The regional market is supported by strong public healthcare systems, increasing adoption of advanced diagnostic technologies, and ongoing influenza surveillance programs. Rising demand for early diagnosis and improved infection control measures continues to contribute to long-term market growth.
The UK market was valued at approximately USD 0.11 billion in 2025. Increasing influenza screening, expanding laboratory testing capacity, and growing adoption of rapid diagnostic technologies continue to support market growth.
Germany's market accounted for approximately USD 0.13 billion in 2025. The country's well-established healthcare infrastructure, strong diagnostic laboratory network, and increasing use of molecular testing technologies continue to strengthen market expansion.
Middle East & Africa accounted for 4.9% of the global influenza diagnostics market, totaling USD 0.09 billion in 2025. Rising healthcare investments, expanding diagnostic capabilities, and growing awareness of infectious disease detection are supporting market growth across the region. Increasing government efforts to improve disease surveillance and healthcare preparedness are expected to create additional opportunities during the forecast period.
The UAE market was valued at approximately USD 0.02 billion in 2025. Government investments in healthcare modernization, increasing use of rapid diagnostic technologies, and expanding infectious disease monitoring programs continue to support market development.
Africa's market reached approximately USD 0.07 billion in 2025. Improving healthcare infrastructure, expanding access to diagnostic testing, increasing public health initiatives, and growing investment in infectious disease surveillance are creating long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Europe Tangential Flow Filtration Market Size, Share & Trends | Industry Report, 2034
Asia Pacific Genetic Testing Market Size, 2034
North America TB Diagnostics Market Size & Trends Analysis, 2034
U.S Direct to Consumer Laboratory Testing Market Size, Share and Forecast to 2034
Non-invasive Prenatal Testing Market Size, Share, Growth, 2034
Vaccines Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com